#United States #Minneapolis #Bio-Techne #Waters Corporation #biotherapeutics

Bio-Techne and Waters Announce Strategic Co-Marketing Partnership

Bio-Techne Corporation, a renowned leader in automated platforms for biotherapeutic characterization, has taken a significant step in advancing the biopharmaceutical landscape. On December 19, 2024, the company announced a strategic co-marketing and co-promotion agreement with Waters Corporation. This collaboration aims to enhance biotherapeutic characterization and development processes, bringing forth innovative solutions that integrate charge separation and liquid chromatography mass spectrometry methodologies.

The strategic partnership leverages the strengths of Bio-Techne's MauriceFlex™ System for charge separation and Waters' BioAccord™ LC-MS System. By combining these complementary technologies, both companies aim to streamline workflows, improve precision, and ultimately expedite the development timelines crucial for biopharma laboratories.

Recent joint activities by both companies in October and November included publishing an application note, hosting a webinar, presenting posters, and participating in talks at notable conferences such as CASSS MS, Festival of Biologics, and PEGS EU. These collaborative efforts showcase both organizations' commitment to pushing the boundaries of biotherapeutic development.

Looking ahead, application scientists from both Bio-Techne and Waters are set to analyze additional classes of biomolecules. They will present their findings at upcoming scientific conferences, further enriching the knowledge base necessary for advancing the field. These findings will also serve as a foundation for upcoming application notes, webinars, and presentations at Bio-Techne User Group Meetings.

Will Geist, President of the Protein Sciences Segment at Bio-Techne, expressed enthusiasm about the partnership, noting, "We are thrilled to see how these new workflows are accelerating biotherapeutic characterization in biopharma labs. Our goal is to continue offering innovative solutions that empower scientists, streamline workflows, and help bring life-saving therapies to market faster."

As part of the agreement, both Bio-Techne and Waters will continue to focus on developing solutions for scientists, decreasing the time it takes to translate discoveries into viable therapies. With Bio-Techne's extensive portfolio featuring hundreds of thousands of products and their significant net sales of approximately $1.2 billion in fiscal 2024, this collaboration is a pivotal move in their strategy to enhance their presence in the life sciences market.

For more information on Bio-Techne’s automated solutions, you can visit their official website, or you can explore Waters’ innovative analytical solutions to understand how these advancements are revolutionizing the field.

In summary, the co-marketing and co-promotion agreement between Bio-Techne Corporation and Waters Corporation mark a significant milestone in biotherapeutic characterization. Their joint efforts promise to deliver state-of-the-art solutions that will not only empower scientific investigations but also streamline the creation of life-saving therapies, making strides in the ever-evolving life sciences domain.